

Introduction to Genomics

Clara Tang

Department of Surgery



LKS Faculty of Medicine
The University of Hong Kong
香港大學李嘉誠醫學院





Dr Li Dak-Sum Research Centre
李達三博士研究中心

Outline of the talk

- Genes, genome and genetic variations
- Identification of genetic factors for human diseases

DNA, genes and chromosomes





Human genome


1990

The Human
Genome Project
began





2001

First draft of the
human genome
released




2003

Human Genome
Project
completion
announced




Human genome

- Human : ~20,000 protein-coding genes
- Mouse : ~22,000 protein-coding genes
- DNA sequences of any two individuals are **>99% identical**




Genetic variations

- A typical genome differs from the reference human genome at **4-5 million sites (genetic variations)**
- In a single genome
 - Majority (>95%) of these genetic variants are common
 - 1–4% have a frequency <0.5% in population



Germline and somatic mutations

- Mutation is one of the sources of genetic variations



Germline mutation is
heritable

Somatic mutation is
NOT inherited

Understanding genetic variations

- Many genetic variations have little or no effect, but some affect the expression and/or functions of genes
- Most of the genetic variations are neutral on fitness
 - Do not affect our ability to survive, adapt or reproduce



Understanding genetic variations


- Some variations lead to or increase risk of diseases

Monogenic diseases

Polygenic diseases

- **Monogenic diseases**

- result from variations in a single gene



Dominant



Recessive



X-linked


- **Polygenic diseases**

- result from variations in more than one genes

Understanding genetic variations

- Some variations lead to or increase risk of diseases


Monogenic diseases



Polygenic diseases

Understanding genetic variations


- Rare **monogenic diseases**
 - It is estimated that over 10,000 of human diseases are known to be monogenic
 - Rare variations in *CFTR* cause cystic fibrosis with various severity



Understanding genetic variations

- Some variations lead to or increase risk of diseases

Monogenic diseases




- Beta thalassemia
- Huntington's disease
- Marfan syndrome
- Rett syndrome
- Tay-Sachs disease


Understanding genetic variations

- Some variations lead to or increase risk of diseases

Monogenic diseases



Polygenic diseases




Understanding genetic variations


■ Genetic factors

■ Environmental factors
- diet, exercise, etc.


Cystic fibrosis





Cholesterol
level



Infectious
disease



Jennifer & Karen
Identical twins born with
genes that absorb fats twice as
fast as the average person




Jennifer
Eats healthy low
fat food



Jennifer
obesity genes
not triggered



Karen
Eats fatty
unhealthy food




Karen
obesity genes
triggered




Genetic risk factors

Genetic studies for genetic risk factors

- *Genetics* is the study of inherited genetic variations
 - To identify genes associated with diseases and traits
 - To improve our health and well-being



The revolution in sequencing technology



The revolution in sequencing technology


First generation sequencing



Next generation sequencing (NGS)




Gene discoveries on rare genetic diseases by new NGS method



Since 2013, NGS have discovered nearly three times as many genes as the conventional approaches for rare genetic diseases

Promise of next generation sequencing (NGS) in healthcare

- Can detect **rare** variants that are deleterious
- Diagnostic yield for **finding the causal variants for rare pediatric diseases** is around 30-70%



Promise of next generation sequencing (NGS) in healthcare



Early diagnosis



Prevention



Rapid
intervention



Precision
treatment




Continuous
assessment

- Studies reported that the molecular diagnosis **affects clinical management** in ~25-50% of these diagnosed patients
 - dietary management, supplement or medications



Genetic studies for genetic risk factors

- *Genetics* is the study of inherited genetic variations
 - To identify genes associated with diseases and traits
 - To improve our health and well-being



Finding genetic risk factors in large scale


- Genomewide association study (**GWAS**)



500,000 to
5 millions
variants

Genetic risk factors identified by GWAS

- As of 2018-10-29, there are >3644 publications
 - reporting ~78236 robust genetic associations
 - with >300 diseases and traits



Summary

- With the recent technological advances, we are now learning more about how each gene works and what it does
- Genetic studies have and will continue to improve our knowledge on the genetic causes of various diseases, which
 - will lead to advances in disease prevention
 - will shed light on healthcare management, treatment and drug development



Thank you

Prof Paul KH Tam
Prof Pak C Sham
Dr Merce Garcia-Barcelo
All labmates

Department of Surgery



**HKU
Med**


LKS Faculty of Medicine
The University of Hong Kong
香港大學李嘉誠醫學院



Dr Li Dak-Sum Research Centre
李達三博士研究中心

Natural human “knockout” by inactivating variations

- Natural human “knockout” can be recognized as “**experiments of nature**”
- ExAC database involving > 60,000 individuals found an average of 120 inactivating genetic variations
 - 85 variations resulting in **1 functional** copy of gene
 - 35 variations resulting in **0 functional** copy of gene



Human “knockout” project

- Studying the human “knockout” can inform
 - gene-level constraint against gene inactivation
 - the functional impact of gene inactivation
- Implication for drug development
 - To **rule-in drug targets**
 - Elimination of *CCR5* protects against HIV infection
 - Elimination of *APOC3* protects against coronary heart disease
 - To **rule-out drug targets**
 - Elimination of *PLA2G7*, that associated with coronary atherosclerosis, demonstrates no protection from cardiovascular disease
 - Such observation matches with result from recent clinical trial




“Genetic superheroes”




Rare genetic variants associated with diseases

- These causal variants can be
 - **Missense** : affecting protein structure
 - **Protein truncating/Loss-of-function (LoF)**
 - resulting in 0 or 1 functional copy of genes compared to 2 functional copies for non-carriers




Understanding genetic variations

- Some variations lead to or increase risk of diseases
- **Polygenic diseases/traits**



Understanding genetic variations


- Some variations lead to or increase risk of diseases
- **Polygenic diseases/traits**



Understanding genetic variations

- Some variations may improve our survivability
- Inactivating variations in *CCR5* gene may delay the progression of AIDS and in some cases bring about immunity, e.g.

- *CCR5*- $\Delta 32$ mutation makes it harder for HIV to bind to the surface of the immune cells and infiltrate them




- CCR5 deficiency may increase risk of symptomatic West Nile virus infection (Glass *et al.* JEM 203(1):35-40)

Genetic risk factors identified by GWAS

- As of 2018-10-29, there are >3644 publications
 - reporting ~78236 robust genetic associations
 - with >300 complex diseases and traits
- Biological insights from discoveries of GWAS
 - Identification of disease-susceptibility genes
 - Implication of new disease-relevant biological pathways
 - Rediscovery of drug targets
 - *DRD2* encoding target for anti-psychotic drug—dopaminergic receptor—is associated with schizophrenia
 - *HMGCR* encoding target for statin is strongly associated with blood lipids including total cholesterol and low-density lipoprotein cholesterol (LDL-C)

Drug targets implicated from GWAS

- Most of the genetic associations detected by GWAS
 - involve **common genetic variants** and
 - the **risks on diseases (effect size)** are **small**



- Effect size does not affect the efficacy of being a drug target
 - **LDL-associated genetic variant** near *HMGCR* decreases LDL-C levels by a modest **2.5 mg/dL**
 - Use of **statins**, which inhibit function of the enzyme encoded by *HMGCR*, typically decreases LDL-C levels by 20–40%, or **~14–70 mg/dL**